Aldeyra Therapeutics, INC. (ALDX) — 8-K Filings

All 8-K filings from Aldeyra Therapeutics, INC.. Browse 25 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (25)

Aldeyra Therapeutics Announces Board and Compensation Changes — Dec 31, 2025 Risk: medium
Aldeyra Therapeutics, Inc. announced on December 23, 2025, changes related to its board of directors and executive compensation. The filing details the departur
8-K Filing — Dec 16, 2025
8-K Filing — Nov 13, 2025
Aldeyra Therapeutics Files 8-K — Oct 28, 2025 Risk: low
Aldeyra Therapeutics, Inc. filed an 8-K on October 28, 2025, reporting other events and financial statements. The company, previously known as Aldexa Therapeuti
Aldeyra Therapeutics Files 8-K — Aug 19, 2025 Risk: low
Aldeyra Therapeutics, Inc. filed an 8-K on August 19, 2025, reporting financial statements and exhibits. The company, incorporated in Delaware, is headquartered
Aldeyra Therapeutics Files 8-K Report — Jul 17, 2025 Risk: low
On July 17, 2025, Aldeyra Therapeutics, Inc. filed an 8-K report. The filing indicates that the company is a pharmaceutical preparations company incorporated in
Aldeyra Therapeutics Files 8-K — Jun 26, 2025 Risk: medium
Aldeyra Therapeutics, Inc. filed an 8-K on June 26, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures, oth
Aldeyra Therapeutics Files 8-K — Jun 17, 2025 Risk: low
On June 17, 2025, Aldeyra Therapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific
Aldeyra Therapeutics Files 8-K on Shareholder Vote Matters — Jun 11, 2025 Risk: low
Aldeyra Therapeutics, Inc. filed an 8-K on June 11, 2025, reporting on a submission of matters to a vote of security holders that occurred on June 10, 2025. The
Aldeyra Therapeutics Files 8-K — May 6, 2025 Risk: low
Aldeyra Therapeutics, Inc. filed an 8-K on May 6, 2025, reporting on events that occurred on May 5, 2025. The filing indicates it is a Regulation FD Disclosure,
Aldeyra Therapeutics Announces Board and Executive Changes — Apr 17, 2025 Risk: medium
Aldeyra Therapeutics, Inc. announced on April 17, 2025, changes related to its board of directors and executive compensation. The filing details the departure o
Aldeyra Therapeutics Files 8-K — Apr 3, 2025 Risk: low
Aldeyra Therapeutics, Inc. filed an 8-K on April 3, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures, oth
Aldeyra Therapeutics Files 8-K: Material Agreement — Nov 18, 2024 Risk: medium
Aldeyra Therapeutics, Inc. announced on November 15, 2024, that it entered into a material definitive agreement. The company also reported other events and file
Aldeyra Therapeutics Files 8-K — Oct 3, 2024 Risk: low
Aldeyra Therapeutics, Inc. filed an 8-K on October 3, 2024, reporting other events and financial statements. The company, previously known as Neuron Systems Inc
Aldeyra Therapeutics Enters Material Agreement, Incurs Financial Obligation — Oct 2, 2024 Risk: medium
Aldeyra Therapeutics, Inc. entered into a material definitive agreement on September 30, 2024, which also created a direct financial obligation for the registra
Aldeyra Therapeutics Announces Board and Compensation Changes — Sep 3, 2024 Risk: low
Aldeyra Therapeutics, Inc. announced on August 29, 2024, changes in its board of directors and executive compensation arrangements. Specifically, the company re
Aldeyra Therapeutics Files 8-K — Aug 8, 2024 Risk: low
Aldeyra Therapeutics, Inc. filed an 8-K on August 8, 2024, to report on other events and financial statements. The filing does not contain specific financial fi
Aldeyra Therapeutics Enters Material Definitive Agreement — Aug 1, 2024 Risk: medium
On August 1, 2024, Aldeyra Therapeutics, Inc. entered into a material definitive agreement. The filing also includes financial statements and exhibits related t
Aldeyra Sells Subsidiary for $10M — Jun 20, 2024 Risk: medium
Aldeyra Therapeutics, Inc. announced on June 20, 2024, that it has entered into a definitive agreement to sell its subsidiary, Adverum Therapeutics, Inc., to a
Aldeyra Therapeutics Files 8-K — Jun 13, 2024 Risk: low
Aldeyra Therapeutics, Inc. filed an 8-K on June 13, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not con
Aldeyra Therapeutics Holds 2024 Annual Meeting — Jun 7, 2024 Risk: low
Aldeyra Therapeutics, Inc. announced on June 4, 2024, that it held its 2024 Annual Meeting of Stockholders. During the meeting, stockholders voted on the electi
Amgen to Acquire Aldeyra Therapeutics for $6.1B — Apr 25, 2024 Risk: medium
Aldeyra Therapeutics, Inc. announced on April 25, 2024, that it has entered into a definitive agreement to be acquired by Amgen Inc. for $6.1 billion, or $29.50
Aldeyra Sells Subsidiary for $50M — Mar 28, 2024 Risk: medium
Aldeyra Therapeutics, Inc. announced on March 28, 2024, that it has entered into a definitive agreement to sell its subsidiary, Adverum Therapeutics, Inc., to a
Aldeyra Therapeutics Files 8-K for Reg FD Disclosure — Feb 13, 2024 Risk: medium
Aldeyra Therapeutics, Inc. filed an 8-K on February 13, 2024, to disclose information under Regulation FD and to include Financial Statements and Exhibits. This
Aldeyra Therapeutics Updates Corporate Contact Info in 8-K Filing — Jan 4, 2024
Aldeyra Therapeutics, Inc. (ALDX) filed an 8-K on January 4, 2024, to update its corporate information, including its business address at 131 Hartwell Avenue, S

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX